Insights+ Key Biosimilars Events of August 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Mylan with its partner Lupin and Biocon launched Nepexto (biosimilar, etanercept) and Semglee (insulin glargine injection) in Germany & in the US, respectively. Additionally, Formycon and Bioeq planned to initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar,…

BySenior EditorSeptember 3, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of June 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Mylan with its partners Lupin and Biocon received MAA for Nepexto (biosimilar, etanercept) in EU and the US FDA's Approval for Semglee (biosimilar, insulin glargine) respectively Our team at PharmaShots has summarized 15 key events of the…

BySenior EditorJuly 3, 2020

EVENTS

Exclusive Webinar: Strategies to Conduct Clinical Trials Effectively in Covid-19 Era

The Webinar on 'Strategies to Conduct Clinical Trials effectively in Covid-19 era' organized by CliniMed LifeSciences Pvt. Ltd., Kolkata in association with Indian Society for Clinical Research (ISCR) and Peerless Hospital, Kolkata as knowledge partners and PharmaShots as a media partner, was held at 3 pm on June 6, 2020. Around 500 plus participants attended…

BySenior EditorJune 18, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of April 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a 'reference…

BySenior EditorMay 8, 2020

EVENTS

Exclusive Coverage: Key Takeaways from the DIA India Medical Devices Conference 2020

The DIA India Medical Devices Conference 2020 is the first effort of DIA India to bring together leaders from the medical devices industry, regulatory and academia from India in New Delhi to discuss the current landscape and regulatory updates of the medical devices industry. New upcoming medical devices regulations, changing landscapes and the evolution of…

ByadminMarch 2, 2020

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2019

1. Pfizer Launched its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019 Date - Oct 01, 2019 Product - Zirabev (biosimilar, bevacizumab) The biosimilar was launched in the US on Dec 31, 2019 following the settlement between Genentech and Pfizer granting all global rights of the product to the Pfizer. In Sept 2019,…

BySenior EditorJanuary 24, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of December 2019

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency In Dec, 2019 Kamada signed a deal with Alvotech for commercialization of biosimilars in Israel while Techno Science also signed an agreement with Kishi Kasei for co-developing biosimilar aflibercept Mylan and Biocon launched its Ogivri (trastuzumab-dkst) in…

BySenior EditorJanuary 17, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of October 2019

Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars 'a reference product to biologics'possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of the biosimilar…

BySenior EditorNovember 1, 2019

INSIGHTS+

Insights+ Key Biosimilars Events of September 2019

Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars 'a reference product to biologics' possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of the…

BySenior EditorOctober 4, 2019

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2019

The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer's Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired…

BySenior EditorSeptember 7, 2019

Insights+ Key Biosimilars Events of August 2020

Insights+ Key Biosimilars Events of June 2020

Exclusive Webinar: Strategies to Conduct Clinical Trials Effectively in Covid-19 Era

Insights+ Key Biosimilars Events of April 2020

Exclusive Coverage: Key Takeaways from the DIA India Medical Devices Conference 2020

PharmaShots’ Key Highlights of Fourth Quarter 2019

Insights+ Key Biosimilars Events of December 2019

Insights+ Key Biosimilars Events of October 2019

Insights+ Key Biosimilars Events of September 2019

PharmaShots’ Key Highlights of Third Quarter 2019

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter